Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi Biologics (Cayman)WXIBF 97 Debt-to-Equity is 0.07 as of Dec. 2025, which is 46% below its 10-year median of 0.13. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $5.23 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 971 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 65.81% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for WuXi Biologics (Cayman)'s Debt-to-Equity or its related term are showing as below:
WXIBF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07 Med: 0.13 Max: 4.18
Current: 0.07
During the past 12 years, the highest Debt-to-Equity Ratio of WuXi Biologics (Cayman) was 4.18. The lowest was 0.07. And the median was 0.13.
WXIBF's Debt-to-Equity is ranked better than 65.81% of 971
companies
in the Biotechnology industry
Industry Median: 0.16
vs WXIBF: 0.07
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
WuXi Biologics (Cayman) Debt-to-Equity Related Terms
WuXi Biologics (Cayman) Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WXIBF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (WXIBF) has a Debt-to-Equity of 0.07 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on WuXi Biologics (Cayman) and its competitors. This is 46% below median its historical median of 0.13. Over the past decade, WuXi Biologics (Cayman)'s Debt-to-Equity has ranged from 0.07 to 4.18. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #332 out of 971 companies in the Biotechnology industry, placing it in the top 34.2%.
Is WuXi Biologics (Cayman)'s Debt-to-Equity too high?
WuXi Biologics (Cayman)'s current Debt-to-Equity of 0.07 is 46% below median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 4.18. The Biotechnology industry median Debt-to-Equity is 0.16. WuXi Biologics (Cayman)'s value of 0.07 is 56.3% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #332 out of 971 companies in the Biotechnology industry, which is above the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #332 out of 971 companies for Debt-to-Equity. This puts WuXi Biologics (Cayman) in the upper half of its industry. The industry median Debt-to-Equity is 0.16. WuXi Biologics (Cayman)'s value of 0.07 is 56.3% below this benchmark. Historically, WuXi Biologics (Cayman)'s own Debt-to-Equity has ranged from 0.07 to 4.18 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 0.16, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 971 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Debt-to-Equity of 0.07 is 56.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Debt-to-Equity is 0.07, which is 46% below median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.23, compared to a current price of $4.65 — trading 11.1% below its estimated fair value. The current Debt-to-Equity is 0.07, which is 46% below median its 10-year median of 0.13 and 56.3% below the Biotechnology industry median of 0.16. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Debt-to-Equity is 0.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.65 is trading 11.1% below its estimated GF Value™ of $5.23.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.
Key valuation signals for WXIBF:
Debt-to-Equity: 0.07 (46% below median its 10-year median of 0.13)
GF Value™: $5.23 vs. price of $4.65 (11.1% below fair value)
Industry Position: 56.3% below the Biotechnology median (#332 of 971)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
